Table 1.
(A) Demographic baseline patient characteristics; (B) length of clopidogrel, aspirin and statin treatment
| Variable | Total (N = 98) |
|---|---|
| (A) Baseline characteristics | |
| Age (years) | |
| Mean | 63.3 |
| SD | 8.5 |
| Median (min, max) | 63 (44, 81) |
| Gender, N (%) | |
| Male/female | 78/20 (79.6/20.4) |
| Race, N (%) | |
| Caucasian | 93 (94.9) |
| Asian oriental | 5 (5.1) |
| Risk factors/comorbidities, N (%) | |
| History of hypertension | 53 (54.1) |
| Hypercholesterolemia | 80 (81.6) |
| Congestive heart failure | 2 (2.0) |
| Prior myocardial infarction | 62 (63.3) |
| Atrial fibrillation | 3 (3.1) |
| Stroke | 4 (4.1) |
| Transient ischemic attack | 5 (5.1) |
| Peripheral arterial disease | 8 (8.2) |
| CABG | 6 (6.1) |
| Peripheral angioplasty or bypass surgery | 1 (1.0) |
| Current smoker | 16 (16.3) |
| Extent of exposure to clopidogrel and ASA and statins | Total (N = 98) Mean; SD |
|---|---|
| (B) Time elapsed from initial clopidogrel administration | |
| Clopidogrel use prior to withdrawal | |
| Duration (days) | 385.8; 62.4 |
| Last dose (mg/day) | 75.0; 0.0 |
| ASA use prior to clopidogrel withdrawal | |
| Duration (days) | 763.5; 1041 |
| Last dose (mg/day) | 101.2; 27.2 |
| Statin use prior to clopidogrel withdrawal | |
| Duration (days) | 887.3; 1394 |
| Last dose (mg/day) | 43.1; 20.5 |